

# Christina Dold

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8289066/publications.pdf>

Version: 2024-02-01

9  
papers

5,595  
citations

1039406

9  
h-index

1473754

9  
g-index

13  
all docs

13  
docs citations

13  
times ranked

11090  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
2	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
4	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
5	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
6	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
7	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe, The</i> , 2022, 3, e21-e31.	3.4	131
8	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	5.8	102
9	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	2.3	24